Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07571499

Helping Young People With Testicular Cancer Using Virtual and Extended Reality

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

View on ClinicalTrials.gov

Summary

TRANSCEND-XR is a European research project designed to better support adolescents and young adults who have been cured of testicular cancer. Even after treatment has ended, many young people continue to face physical, psychological, or social difficulties that are often poorly understood and insufficiently addressed. The project aims to develop an innovative digital tool using extended reality (XR) to help these young people better understand the potential long-term effects of the disease and its treatments, recognize signs that require medical attention, and become more active participants in their own health follow-up. TRANSCEND-XR first includes a pilot phase to test feasibility and improve the tool, followed by a larger clinical study comparing its use with usual medical follow-up. Researchers will assess, in particular, its impact on patients' knowledge, quality of life, and ability to seek help. The ultimate goal is to sustainably improve information, autonomy, and well-being among young survivors of testicular cancer through a digital approach tailored to their needs and daily practices.

Official title: Addressing TesticulaR cANcer Unmet Supportive CarE NeeDs in Adolescents and Young Adults Using eXtended Reality

Key Details

Gender

MALE

Age Range

15 Years - 39 Years

Study Type

INTERVENTIONAL

Enrollment

245

Start Date

2027-01-04

Completion Date

2029-06-30

Last Updated

2026-05-06

Healthy Volunteers

Conditions

Testicular Cancer Testis Cancer AYA Cancer Survivors Survivor Patients

Interventions

OTHER

Digital tool using extended reality

TRANSCEND-XR is a digital educational intervention based on extended reality (XR), designed for adolescents and young adults who have completed curative treatment for testicular cancer. It provides interactive and immersive content aimed at improving understanding of the late effects of treatment, whether physical, psychological, or social. The tool helps users recognize symptoms that require medical attention, strengthen their health knowledge, and adopt behaviors that support long-term follow-up, such as self-examination and appropriate use of healthcare services. Co-designed with patients and healthcare professionals, TRANSCEND-XR aims to enhance autonomy, confidence, and engagement of young survivors in managing their health after cancer.

Inclusion Criteria: 1. Any person assigned male at birth who is diagnosed with stage I-III TC (germ cell tumour of the testicles). 2. Aged between 15 and 39 years at the time of study inclusion. 3. Completed curative treatment comprising of at least one standard treatment modality (surgery, chemotherapy and/or radiotherapy) for treatment of their cancer. A maximum of 9 months from the end of curative treatment will be allowed. 4. Permitted treatment modalities: * Localised disease: orchiectomy with or without chemotherapy and/or radiotherapy. * Metastatic disease: orchiectomy and chemotherapy or radiotherapy or retroperitoneal surgery, or a combination of aforementioned treatments. First-line treatment only allowed. 5. Willing and able to provide a valid and signed informed consent and/or assent, as appropriate. 6. ECOG performance status 0-2. 7. Patients accept to use personal smartphone 8. Patients able to read and understand the local language Exclusion Criteria: 1. Non-testicular germ cell tumours (e.g., mediastinal primary or retroperitoneal primary tumours). 2. Non-germ cell TC. 3. Previous chemotherapy, radiotherapy, or surgery for TC other than that allowed in IC 4. 4. History of contralateral TC. 5. Any illness that would prevent the AYA TC survivor from giving a valid and signed informed consent, as assessed by the investigator. 6. Any illness that might be exacerbated by the use of an XR digital tool, as assessed by the investigator, including history of severe motion sickness, brain lesions and epilepsy. 7. Uncontrolled medical condition such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease (including but not limited to grade 2 or higher cardiac failure, arrythmia, unstable angina, history of myocardial infract in the 6 months which, in the opinion of the treating physician, would influence the assessment of long-term side effect of TC treatment. 8. AYA TC survivors with a "currently active" second malignancy other than non-melanoma skin cancers, superficial non-invasive (pTa or pTis) TCC of the bladder, or intratubular germ cell neoplasia. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years. 9. Chemotherapy or radiotherapy for malignant disease other than TC within the past 3 years.